A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

NCT06600789

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Carrick Therapeutics Limited
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (8)

- Histopathologically or cytologically confirmed diagnosis of malignant disease evaluable by RECIST v1.1
- Provision of signed written informed consent before any study-related activities, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures and willing to permit access to stored historical tumor tissue, prior tumor radiological assessments and tumor biomarker data.
- ECOG performance status of d 2 with no deterioration over the previous 2 weeks.
- Ability to take oral medications and be willing to record daily adherence to the study drug.
- Women either of non-childbearing potential, either confirmed to be post-menopausal or of childbearing potential willing to practice effective contraception for the duration of the study and for minimum 33 days after the last dose of CT7439.

... and 3 more (see full listing online)

Exclusion (18)

- Prior therapy with a specific CDK12/13 inhibitor, within any timeframe prior to the first dose of CT7439.
- Participants with any other malignancy that have been active or treated within the past 3 years prior to enrolment, with the exception of cervical intraepithelial neoplasia and non-melanoma skin cancer.
- Any unresolved toxicity (except alopecia) from prior therapy of e 2 Common Terminology Criteria for Adverse Events (CTCAE) Grade.
- Active or documented history of autoimmune disease.
- Any current or prior central nervous system metastases

... and 13 more (see full listing online)

Locations (6 total)

Research site 03, Dallas, Texas, United States
Research site 01, San Antonio, Texas, United States
Research site 02, Fairfax, Virginia, United States
... and 3 more locations